keyword
MENU ▼
Read by QxMD icon Read
search

antiemetics for chemotherapy

keyword
https://www.readbyqxmd.com/read/28427442/effect-of-acupuncture-in-prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-advanced-cancer-study-protocol-for-a-randomized-controlled-trial
#1
Qi-Wei Li, Ming-Wei Yu, Guo-Wang Yang, Xiao-Min Wang, Huan Wang, Chen-Xi Zhang, Na Xue, Wei-Ru Xu, Qi Fu, Zhong Yang, Lin Yang
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing side effects in patients with cancer. The introduction and development of antiemetic drugs have significantly improved the ability of clinicians to control CINV, but it is not easy to translate to practical application, owing to financial issues, provider-related barriers, and patient factors. Nondrug therapies are needed to alleviate the symptoms of CINV. Acupuncture is an appropriate adjunctive treatment for CINV, but additional evidence is needed...
April 20, 2017: Trials
https://www.readbyqxmd.com/read/28418944/the-benefit-of-pro-re-nata-antiemetics-provided-with-guideline-consistent-antiemetics-in-delayed-nausea-control
#2
Sun Young Rha, Joohyuk Sohn, Gun Min Kim, Hye Ryun Kim, Jiyeon Lee
BACKGROUND: Delayed nausea after chemotherapy remains a symptom of interest. Clinicians often provide additional and/or pro re nata (p.r.n.) antiemetics with guideline-consistent antiemetics in an attempt to achieve further symptom control. Whether the usage of additional and/or p.r.n. antiemetics provide added benefit remains as a question. OBJECTIVE: The purpose of this study was to determine the benefit of providing additional antiemetics and/or p.r.n. antiemetics with guideline-consistent antiemetics in the control of nausea, functioning, and quality of life (QOL)...
April 17, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28396308/new-options-and-controversies-in-the-management-of-chemotherapy-induced-nausea-and-vomiting
#3
Sara M Koth, Jill Kolesar
PURPOSE: An expanding array of options for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), including regimens containing olanzapine or recently approved neurokinin 1 (NK1) receptor antagonists, are reviewed. SUMMARY: Up to 80% of patients receiving chemotherapy have CINV. Current practice guidelines recommend that patients treated with highly emetogenic chemotherapy also receive a 3-drug antiemetic regimen initiated on the day of and continued for 3 days after chemotherapy administration, with the most commonly used 3-drug regimen consisting of an NK1 receptor antagonist, a 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, and dexamethasone...
April 10, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28395603/chemotherapy-induced-nausea-and-vomiting-cinv-in-190-colorectal-cancer-patients-a-prospective-registration-study-by-the-cinv-study-group-of-japan
#4
Yasushi Tsuji, Hideo Baba, Koji Takeda, Michiya Kobayashi, Eiji Oki, Masahiro Gotoh, Kazuhiro Yoshida, Mototsugu Shimokawa, Yoshihiro Kakeji, Keisuke Aiba
PURPOSE: Chemotherapy is an indispensable therapeutic approach for colorectal cancer both in the adjuvant and metastatic setting. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, many aspects of CINV in patients with colorectal cancer remain unclear. METHODS: This multicenter, prospective, observational study analyzed the data of 190 colorectal cancer patients scheduled for moderately emetogenic chemotherapy (MEC)...
April 11, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28376213/neurokinin-1-receptor-antagonist-based-triple-regimens-in-preventing-chemotherapy-induced-nausea-and-vomiting-a-network-meta-analysis
#5
Yaxiong Zhang, Yunpeng Yang, Zhonghan Zhang, Wenfeng Fang, Shiyang Kang, Youli Luo, Jin Sheng, Jianhua Zhan, Shaodong Hong, Yan Huang, Ningning Zhou, Hongyun Zhao, Li Zhang
Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown. Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases...
February 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28373467/efficacy-of-single-dose-first-generation-5-ht3-receptor-antagonist-and-dexamethasone-for-preventing-nausea-and-vomiting-induced-by-low-dose-carboplatin-based-chemotherapy
#6
Daizo Kaito, Hirotoshi Iihara, Norihiko Funaguchi, Junki Endo, Fumitaka Ito, Komei Yanase, Sayaka Toyoshi, Yuka Sasaki, Chiemi Hirose, Natsumi Arai, Mika Kitahora, Yasushi Ohno, Yoshinori Itoh, Shinya Minatoguchi
BACKGROUND: Carboplatin (CBDCA) is known to exhibit a high emetic risk among moderate-emetic risk anticancer drugs, and the dose of CBDCA varies in different therapies. In concurrent chemoradiotherapy (CCRT) for non-small cell lung cancer (NSCLC), the weekly administration of CBDCA (area under the curve (AUC) 2 mg/ml/min) and paclitaxel (PTX: 40 mg/m(2)) is frequently applied as standard therapy. However, the optimal antiemetic measures in the use of such low-dose CBDCA remain unclear...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28365889/antiemetic-therapy-for-non-anthracycline-and-cyclophosphamide-moderately-emetogenic-chemotherapy
#7
REVIEW
Naoki Inui
Although antiemetic management in cancer therapy has improved, chemotherapy-induced nausea and vomiting remain common and troubling adverse events. Chemotherapeutic agents are classified based on their emetogenic effects, and appropriate antiemetics are recommended according to this categorization. Chemotherapy categorized as moderately emetogenic is associated with a wide spectrum of emetic risks. Combined anthracycline and cyclophosphamide regimens have been recently reclassified as highly emetogenic chemotherapy regimen...
May 2017: Medical Oncology
https://www.readbyqxmd.com/read/28362229/late-chronotypes-are-associated-with-neoadjuvant-chemotherapy-induced-nausea-and-vomiting-in-women-with-breast-cancer
#8
Kwang-Min Lee, Doo-Young Jung, Heesung Hwang, Won-Hyoung Kim, Joo-Young Lee, Tae-Yong Kim, Seock-Ah Im, Kyung-Hun Lee, David Spiegel, Bong-Jin Hahm
Neoadjuvant chemotherapy, that is, the administration of chemotherapy before surgery, has been commonly used for locally advanced breast cancer to improve the surgical outcomes and increase the opportunity for breast-conserving therapy. Women with breast cancer often receive an anthracycline-based regimen as the neoadjuvant chemotherapy, which is associated with a high risk of emesis. Despite the development of novel antiemetics, chemotherapy-induced nausea and vomiting (CINV) has been commonly reported as a major adverse effect, affecting the quality of life of the patients...
2017: Chronobiology International
https://www.readbyqxmd.com/read/28327932/integrated-safety-analysis-of-rolapitant-with-coadministered-drugs-from-phase-ii-iii-trials-an-assessment-of-cyp2d6-or-bcrp-inhibition-by-rolapitant
#9
S Barbour, T Smit, X Wang, D Powers, S Arora, V Kansra, M Aapro, J Herrstedt
Background: Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in patients administered moderately or highly emetogenic chemotherapy. Unlike other NK 1 RAs, rolapitant does not inhibit or induce cytochrome P450 (CYP) 3A4, but it does inhibit CYP2D6 and breast cancer resistance protein (BCRP). To analyze potential drug-drug interactions between rolapitant and concomitant medications, this integrated safety analysis of four double-blind, randomized phase II or III studies of rolapitant examined adverse events by use versus non-use of drug substrates of CYP2D6 or BCRP...
February 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28281050/a-cost-utility-analysis-of-risk-model-guided-versus-physician-s-choice-antiemetic-prophylaxis-in-patients-receiving-chemotherapy-for-early-stage-breast-cancer-a-net-benefit-regression-approach
#10
Kednapa Thavorn, Doug Coyle, Jeffrey S Hoch, Lisa Vandermeer, Sasha Mazzarello, Zhou Wang, George Dranitsaris, Dean Fergusson, Mark Clemons
PURPOSE: We assessed the cost-effectiveness of a risk model-guided (RMG) antiemetic prophylaxis strategy compared with the physician's choice (PC) strategy in patients receiving chemotherapy for early-stage breast cancer. METHODS: We conducted a cost-utility analysis based on a published randomized controlled trial of 324 patients with early-stage breast cancer undergoing chemotherapy at two Canadian cancer centers. Patients were randomized to receive their antiemetic treatments according to either predefined risk scores or the treating physician's preference...
March 9, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28270854/antiemetic-and-myeloprotective-effects-of-rhus-verniciflua-stoke-in-a-cisplatin-induced-rat-model
#11
Hyo-Seon Kim, Hyeong-Geug Kim, Hwi-Jin Im, Jin-Seok Lee, Sung-Bae Lee, Won-Yong Kim, Hye-Won Lee, Sam-Keun Lee, Chang Kyu Byun, Chang-Gue Son
Rhus verniciflua Stoke has been commonly used in traditional medicine to treat gastrointestinal (GI) dysfunction diseases. In order to investigate pharmacological properties of Rhus verniciflua Stoke water extract (RVX) on cisplatin-induced amnesia, RVX (0, 25, 50, or 100 mg/kg) was orally administrated for five consecutive days after a single intraperitoneal injection of cisplatin (6 mg/kg) to SD rat. Cisplatin injection significantly increased the kaolin intake (emesis) but reduced the normal diet intake (anorexia) whereas the RVX treatment significantly improved these abnormal diet behaviors at both the acute and delayed phase...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28244483/weekly-cisplatin-30-40-mg-m-2-as-radiosensitizer-is-it-high-or-moderate-emetic-agent
#12
A Karpe, V M Patil, A Joshi, V Noronha, S Gupta, A Ramaswamy, A Sahu, V Doshi, T Gupta, S Rath, S Banavali, K Prabhash
PURPOSE: The American Society of Clinical Oncology (ASCO) guideline recommends a high antiemetic prophylaxis for any dose of cisplatin. This hypothesis was tested by us in this analysis of solid tumor patients who received weekly cisplatin as a radiosensitizer in a dose range of 30-40 mg/m2. METHODS: This was a retrospective analysis of 181 solid tumor patients who received weekly cisplatin (in the dose range of 30-40 mg/m2) as a radiosensitizer between July 2015 and August 2015...
July 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28243404/effect-of-persian-medicine-remedy-on-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-a-double-blind-randomized-crossover-clinical-trial
#13
Mohammad Nazari, Ali Taghizadeh, Mojtaba Mousavi Bazzaz, Hassan Rakhshandeh, Sadegh Shokri
BACKGROUND: Chemotherapy induced nausea and vomiting (CINV) is a side effect, and has negative effect on quality of life and continuation of chemotherapy. Despite new regimen and drugs, the problems still remain and standard guidelines, effective treatment and supportive care for refractory CINV are still not yet established. Persian medicine, the old Iranian medical school, offer Persumac (prepared from Rhus Coriaria and Bunium Persicum Boiss). OBJECTIVE: The specific objectives were to assess the effect of Persumac on the number and severity of nausea and vomiting in refractory CINV in acute and delayed phase...
January 2017: Electronic Physician
https://www.readbyqxmd.com/read/28205315/prevention-of-chemotherapy-induced-vomiting-in-children-receiving-multiple-day-cisplatin-chemotherapy-a-hospital-based-retrospective-cohort-study
#14
Kenji Kishimoto, Keiichiro Kawasaki, Atsuro Saito, Aiko Kozaki, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka
BACKGROUND: Optimal prevention of chemotherapy-induced vomiting (CIV) has not been established for patients receiving cisplatin in divided doses. The aim of this study was to describe the incidence and risk factors of CIV in children who received multiple-day cisplatin chemotherapy. PROCEDURE: A total of 24 consecutive pediatric patients (age 0-19 years) who received multiple-day cisplatin chemotherapy in our hospital were enrolled. Patients with relapsed disease or primary intracranial tumor and those who received concurrent radiation therapy were excluded...
February 16, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28198358/combination-of-aprepitant-azasetron-and-dexamethasone-as-antiemetic-prophylaxis-in-women-with-gynecologic-cancers-receiving-paclitaxel-carboplatin-therapy
#15
Masafumi Koshiyama, Noriomi Matsumura, Saeko Imai, Koji Yamanoi, Kaoru Abiko, Yumiko Yoshioka, Ken Yamaguchi, Junzo Hamanishi, Tsukasa Baba, Ikuo Konishi
BACKGROUND The aim of this study was to evaluate the antiemetic effect of aprepitant and to determine how to provide triple combination therapy (aprepitant/azasetron/dexamethasone) to women receiving paclitaxel/carboplatin moderately emetogenic chemotherapy (MEC). MATERIAL AND METHODS The current study was a prospective study of 163 women with gynecologic cancers. We compared the digestive symptoms scores (nausea, vomiting, appetite loss, and dietary intake) of 37 women with ovarian cancers before and after aprepitant administration...
February 15, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28194109/delayed-chemotherapy-induced-nausea-and-vomiting-pathogenesis-incidence-and-current-management
#16
REVIEW
Bernardo L Rapoport
Even when chemotherapy-induced nausea and vomiting (CINV) can be effectively controlled in the acute phase, it may still occur in the delayed phase. Identifying at-risk patients is complex and requires consideration of clinical, personal, demographic, and behavioral factors. Delayed CINV has a significant detrimental effect on patients' daily life and is responsible for significant healthcare resource utilization. Patients who do not experience acute CINV are not necessarily exempt from delayed CINV, and healthcare professionals have been shown to underestimate the incidence of delayed CINV...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28193133/integrative-therapeutic-approaches-for-the-management-and-control-of-nausea-in-children-undergoing-cancer-treatment
#17
Tha'er G Momani, Donna L Berry
Chemotherapy-induced nausea and vomiting (CINV) continues to be a common symptom experienced by children undergoing cancer treatment despite the use of contemporary antiemetics. Integrative therapeutic approaches in addition to standard pharmacologic antiemetic regimes offer potential to control CINV. The purpose of this review was to identify current evidence on integrative therapeutic approaches for the control of CINV in children with cancer. Online search engines (PubMed, CINAHL, PsychINFO) were queried using MESH terms...
February 1, 2017: Journal of Pediatric Oncology Nursing: Official Journal of the Association of Pediatric Oncology Nurses
https://www.readbyqxmd.com/read/28191518/corticosteroids-the-oldest-agent-in-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-what-about-the-guidelines
#18
Florence Van Ryckeghem
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most disturbing side effects of cancer treatment. Research in antiemetic therapy has progressed gradually since the early eighties, and the development of antiemetic agents continues. This review focuses on the current management of CINV based on the most recent guidelines, and adherence to the latter is examined more carefully. Setrons (5HT3 receptor antagonists), corticosteroids, and NK-1 receptor antagonists are the cornerstones of antiemetic therapy...
April 1, 2016: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/28160217/a-randomized-controlled-trial-of-nabilone-for-the-prevention-of-acute-postoperative-nausea-and-vomiting-in-elective-surgery
#19
RANDOMIZED CONTROLLED TRIAL
David Neville Levin, Zachary Dulberg, An-Wen Chan, Gregory M T Hare, C David Mazer, Aaron Hong
PURPOSE: Nabilone is a synthetic cannabinoid with properties that make it an appealing candidate as a postoperative nausea and vomiting (PONV) prophylactic adjunct. Nabilone has proven clinical utility in chemotherapy-related nausea and vomiting but has not been adequately tested for PONV. The purpose of this study was to evaluate the effectiveness of a single dose of nabilone for the prevention of PONV. METHODS: This was a pragmatic single-centre randomized-controlled trial comparing oral nabilone vs placebo for the prevention of PONV...
April 2017: Canadian Journal of Anaesthesia, Journal Canadien D'anesthésie
https://www.readbyqxmd.com/read/28160077/effectiveness-of-antiemetic-triplet-therapy-with-aprepitant-palonosetron-and-dexamethasone-for-gynecologic-cancer-patients-receiving-carboplatin-and-paclitaxel-a-prospective-single-arm-study
#20
Fuminori Ito, Naoto Furukawa
PURPOSE: There is no positive evidence for the efficacy of antiemetic triplet therapy with aprepitant (APR), palonosetron (PALO), and dexamethasone (DEX) for moderate emetogenic chemotherapy, especially for gynecologic malignancies. Thus, the present study evaluated the efficacy of this triplet therapy in patients receiving carboplatin and paclitaxel (CP) for gynecologic malignancy. METHODS: Seventy patients with gynecologic cancer receiving CP were enrolled into a prospective single-arm study with APR (125 mg on day 1, 80 mg on days 2-3), PALO (0...
February 4, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
32975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"